But maybe Edgar to start with you and with your expertise in the condition of autosomal dominant polycystic kidney disease, ...

It has been prompted by fresh data from a new cohort of patients in its phase 1b trial of RGLS8429 in ADPKD, a leading cause of end-stage renal disease, which affects around 160,000 people in the ...

as well as delay progression of disease severity in ADPKD. In March 2025, Regulus announced the successful completion of its phase 1b multiple-ascending dose clinical trial for farabursen. The phase ...

The positive data came from Cohort 4 of this phase 1b study, using farabursen to treat these ADPKD patients. Specifically, a total of 26 patients were given a fixed dose of 300 mg of this drug ...

Regulus (RGLS) announced positive topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen for the treatment of autosomal dominant polycystic kidney disease ...

Real-world data supports tolvaptan use to slow kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD).

Regulus' phase 1b data showed that miR-17-directed oligonucleotide farabursen achieved reductions in an ADPKD biomarker (polycystin) and slowed down the increase in kidney size that occurs in ...

which recently completed a Phase 1b study in people with autosomal dominant polycystic kidney disease, or ADPKD. Per deal terms, Regulus shareholders will receive $7 in cash per share, a premium ...